Roxi-AI provides a longitudinal, outcomes-linked risk signals database for the life sciences industry. Its predictive models analyze time-stamped clinical, regulatory, and commercial data to uncover hidden patterns in biopharma assets. This service systematically de-risks portfolios, enabling sharper investment and development decisions for funds and biopharma companies.
Funding
Funding not disclosed
Founders
Product
Problem
Biopharmaceutical companies face inefficiencies in selecting and de-risking therapeutic assets, leading to lost time, capital, and delayed patient access to novel therapies. The subjective nature of traditional evaluation processes often results in suboptimal portfolio decisions.
Solution
Roxi-AI provides an AI-powered platform for objective risk assessment and benchmarking of biopharmaceutical assets. The platform integrates diverse datasets and applies advanced analytics to evaluate assets across critical parameters, enabling data-driven decision-making. This approach standardizes the evaluation process, mitigates inherent risks, and optimizes portfolio selection for commercial success. By offering quantitative insights and comparative analysis, Roxi-AI empowers organizations to confidently prioritize and advance their therapeutic pipelines.
Target Audience
The primary customers are biopharmaceutical companies, clinical development service providers, and investors involved in asset evaluation and portfolio management.
Features
- Proprietary 100-point risk evaluation system for comprehensive asset risk assessment.
- AAA-D graded risk scoring for biopharmaceutical assets, providing a standardized rating.
- Industry benchmarking capabilities to compare asset risk profiles against market standards.
- Predictive modeling to assess the likelihood of commercial success for therapeutic assets.
- A deal marketplace facilitating connections between biopharmaceutical companies and investors.
- Data integration engine designed to ingest and process disparate data sources.
- AI and advanced analytics models for risk quantification and mitigation strategy development.